NZ582390A - Cd44 splice variants in neurodegenerative diseases - Google Patents

Cd44 splice variants in neurodegenerative diseases

Info

Publication number
NZ582390A
NZ582390A NZ582390A NZ58239008A NZ582390A NZ 582390 A NZ582390 A NZ 582390A NZ 582390 A NZ582390 A NZ 582390A NZ 58239008 A NZ58239008 A NZ 58239008A NZ 582390 A NZ582390 A NZ 582390A
Authority
NZ
New Zealand
Prior art keywords
seq
coordinates
combination
sequence
disease
Prior art date
Application number
NZ582390A
Other languages
English (en)
Inventor
Elhanan Pinner
Moshe Laudon
Nava Zisapel
Original Assignee
Neurim Pharma 1991
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991
Publication of NZ582390A publication Critical patent/NZ582390A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychology (AREA)
NZ582390A 2007-07-10 2008-07-10 Cd44 splice variants in neurodegenerative diseases NZ582390A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92970607P 2007-07-10 2007-07-10
PCT/IB2008/052786 WO2009007934A2 (en) 2007-07-10 2008-07-10 Cd44 splice variants in neurodegenerative diseases

Publications (1)

Publication Number Publication Date
NZ582390A true NZ582390A (en) 2012-05-25

Family

ID=40229192

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ582390A NZ582390A (en) 2007-07-10 2008-07-10 Cd44 splice variants in neurodegenerative diseases

Country Status (15)

Country Link
US (2) US9018180B2 (OSRAM)
EP (1) EP2167692B1 (OSRAM)
JP (1) JP2010532989A (OSRAM)
KR (1) KR20100044793A (OSRAM)
CN (1) CN101821407B (OSRAM)
AU (1) AU2008273713B2 (OSRAM)
BR (1) BRPI0814685A2 (OSRAM)
CA (1) CA2692861A1 (OSRAM)
EA (1) EA201070108A1 (OSRAM)
ES (1) ES2423182T3 (OSRAM)
IL (1) IL203130A (OSRAM)
MX (1) MX2010000236A (OSRAM)
NZ (1) NZ582390A (OSRAM)
WO (1) WO2009007934A2 (OSRAM)
ZA (1) ZA201000083B (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101945869B (zh) 2007-12-19 2014-06-18 癌症研究技术有限公司 吡啶并[2,3-b]吡嗪-8-取代化合物及其用途
US8815896B2 (en) 2010-02-01 2014-08-26 The Institute Of Cancer Research: Royal Cancer Hospital 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
BR112013024323A2 (pt) * 2011-03-24 2017-06-13 Neurim Pharmaceuticals ( 1991 ) Ltd peptídeos neuroprotetores
US9399779B2 (en) * 2011-06-08 2016-07-26 The Corporation Of Mercer University Alternative splicing constructs and methods of use
CN104277092B (zh) * 2013-07-12 2017-10-31 天津医科大学 用于预防和/或治疗老年性痴呆的β片层阻断肽
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
US10400009B2 (en) 2014-09-04 2019-09-03 Tianjin Medical University β-sheet breaker peptide used for preventing and/or treating alzheimer's disease
CN107815438A (zh) * 2017-08-02 2018-03-20 清华大学 重组细胞、筛选l型钙通道调节剂的方法、试剂在制备药物中的用途和药物组合物
CN117377777A (zh) 2021-05-11 2024-01-09 纽瑞姆制药（1991）有限公司 诊断和治疗具有2号染色体2:107,510,000-107,540,000基因座单核苷酸多态性受试者的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990299A (en) * 1995-08-14 1999-11-23 Icn Pharmaceuticals, Inc. Control of CD44 gene expression for therapeutic use
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6150162A (en) 1998-12-17 2000-11-21 Isis Pharmaceuticals Inc. Antisense modulation of CD44 expression
IL133647A0 (en) * 1999-06-08 2001-04-30 Yissum Res Dev Co Novel cd44 variant
WO2002081628A2 (en) * 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
DK2796553T3 (da) 2000-03-30 2019-09-30 Whitehead Inst Biomedical Res Rna-sekvensspecifikke formidlere af rna-interferens
CZ302719B6 (cs) * 2000-12-01 2011-09-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití
WO2002076510A1 (en) 2001-03-23 2002-10-03 Agy Therapeutics Use of biomolecular targets in the treatment and visualization of brain tumors
WO2002097044A2 (en) 2001-05-25 2002-12-05 Thomas Jefferson University Alternative splice forms of proteins as basis for multiple therapeutic modalities
US7833779B2 (en) * 2001-07-25 2010-11-16 Jivan Biologies Inc. Methods and systems for polynucleotide detection
JP2007508810A (ja) * 2003-09-30 2007-04-12 エヴォテック ニューロサイエンシス ゲゼルシャフト ミット ベシュレンクテル ハフツング スルホトランスフェラーゼの神経変性疾患に関する診断的および治療的使用
JP2008546379A (ja) * 2005-06-16 2008-12-25 エボテツク・ニユーロサイエンシーズ・ゲー・エム・ベー・ハー 神経変性疾患のための診断および治療の標的ａｄａｒｂ２タンパク質

Also Published As

Publication number Publication date
ZA201000083B (en) 2011-03-30
CN101821407B (zh) 2013-09-18
US20150266940A1 (en) 2015-09-24
CN101821407A (zh) 2010-09-01
MX2010000236A (es) 2010-06-02
EP2167692A2 (en) 2010-03-31
BRPI0814685A2 (pt) 2019-09-24
US9416166B2 (en) 2016-08-16
HK1145856A1 (en) 2011-05-06
WO2009007934A3 (en) 2009-05-07
JP2010532989A (ja) 2010-10-21
EA201070108A1 (ru) 2010-06-30
ES2423182T3 (es) 2013-09-18
CA2692861A1 (en) 2009-01-15
KR20100044793A (ko) 2010-04-30
IL203130A (en) 2014-07-31
US20110172286A1 (en) 2011-07-14
AU2008273713A1 (en) 2009-01-15
AU2008273713B2 (en) 2014-07-03
US9018180B2 (en) 2015-04-28
WO2009007934A2 (en) 2009-01-15
EP2167692B1 (en) 2013-05-22

Similar Documents

Publication Publication Date Title
US9416166B2 (en) CD44 splice variants in neurodegenerative diseases
Kumamoto et al. Hyperactivation of midbrain dopaminergic system in schizophrenia could be attributed to the down-regulation of dysbindin
US10337068B2 (en) TRPC6 involved in glomerulonephritis
WO2013181618A2 (en) Methods to treat alzheimer's disease using apoe inhibitors
US20080038730A1 (en) Diagnostic and Therapeutic Use of Kcnj6 for Alzheimer's Disease
US20060259991A1 (en) Diagnostic and therapeutic use of scn2b protein for neurodegeneraative diseases
EP1776591B1 (en) Diagnostic and therapeutic use of a plasma membrane atpase
US20080051334A1 (en) Diagnostic and Therapeutic Use of Kcnc1 for Neurodegenerative Diseases
EP1888783A2 (en) Kcnn3 as diagnostic and therapeutic target for neurodegenerative diseases
KR102601020B1 (ko) 파골 세포 분화 조절용 조성물 및 이의 용도
EP1721008B1 (en) Diagnostic and therapeutic use of mal2 gene and protein for neurodegenerative diseases
CA2590751A1 (en) Polynucleotides and polypeptide sequences involved in the process of bone remodeling
HK1145856B (en) Cd44 splice variants in neurodegenerative diseases
JP2006518199A (ja) 神経変性疾患に対するｓｃｎ２ｂタンパク質の診断的かつ治療的使用
JP2007532610A (ja) Ｋｃｎｃ１の神経変性疾患に関する診断的および治療的用途
WO2007101991A1 (en) Target for the enhancement qf cognitive function

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JUL 2016 BY CPA GLOBAL

Effective date: 20150601

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JUL 2017 BY CPA GLOBAL

Effective date: 20160603

LAPS Patent lapsed